<DOC>
	<DOCNO>NCT01335620</DOCNO>
	<brief_summary>This phase I , open label , prospective , one phase pharmacokinetic observational study . Twenty HIV-1 infected subject recruit . Eligible subject currently receive stable antiretroviral therapy undetectable plasma HIV RNA evidence previous HIV- resistance mutation genotypic resistance testing . At baseline , subject switch antiretroviral therapy : - tenofovir/emtricitabine 245/200 mg daily ( Truvadaâ„¢ ) plus - raltegravir 400 mg twice daily On day 28 , subject attend intensive 24 hour pharmacokinetic visit . Follow 6 month , subject attend day 14 , 90 180 follow visit include standard safety parameter . Assessment cardiac biomarkers baseline day 90 180 assessment neurocognitive function screening , baseline day 180 also undertaken . Following completion study , subject recommence usual antiretroviral treatment regimen attend study follow visit .</brief_summary>
	<brief_title>The Raltegravir 60+ Study</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIV1 infect male female 2 . 60 year age greater* 3. sign inform consent 4. willing switch therapy per study protocol 5. previous exposure raltegravir HIV1 integrase inhibitor 6. plasma HIV RNA &lt; 50 copies/mL screen least one occasion last 3 month 7. currently receive stable antiretroviral regimen antiretroviral drug switch least 3 month 8. previous clinicallysignificant resistance document HIV1 genotypic resistance 9. subject good health upon medical history , physical exam , laboratory test 10 . BMI equal 18 32 11 . Male subject heterosexually active must use two form barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse , screen completion study . 12 . Have local screen laboratory result ( haematology chemistry fall within normal range central laboratory 's reference range unless result determine Investigator clinical significance * 50 % total enrol cohort 65 year age . Subsequent 10 subject age 60 64 recruit , subject age 65 eligible . 1. current alcohol abuse drug dependence 2. positive urine drug abuse screen 3. active opportunistic infection significant comorbidities 4. current disallow concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>